Profile avatar
conejo-garcia.bsky.social
30 posts 35 followers 33 following
Prolific Poster

This study, with Fred Locke as corresponding author, shows that allogeneic CAR T cells can elicit durable complete responses against lymphoma. CART persistence>4 months. No severe CRS and no GVHD, paving the way for a new geenration of "off-the-shelf" CART ascopubs.org/doi/10.1200/...

Registration for the 12th Annual Southeastern Immunology Symposium in bautiful Charlottesville is now available: www.immunology.virginia.edu/sis2025/inde...

A gentle reminder that abstract submissions for the #gdTcells conference close on March 15. 👉🏼 na.eventscloud.com/website/7048...

This is a brave opinion from Harold Varmus on the ongoing slaughter of Science. Why is not everybody else puzzled about the complicit silence of industry in this mess? www.nytimes.com/2025/02/14/o...

NIH cuts to indirect rates, currently blocked by a federal judge, are already negatively affecting the stock of multiple companies. Yet industry does not speak up. Existing synergy between Academia and industry is at risk. www.genengnews.com/topics/omics... via @GENbio

Trump Cuts Target Next Generation of Scientists and Public Health Leaders www.nytimes.com/2025/02/18/u...

Second top NIH official, who oversaw awarding of research grants, departs abruptly www.statnews.com/2025/02/13/n... via @statnews.com

Funny that the $4B they want to save is the same amount SpaceX got last year in gov't contracts. That even paid the SpaceX CEO $4M! Rockets might be cool and all, but if choosing between rockets and life-saving medicine..You know, maybe the rich guy who wants to play with rockets should pay himself.

Does somebody know whether the acting NIH director agrees with slashing NIH grants? He should be aware of the devasting effect of this action. www.statnews.com/2025/01/24/t... via @statnews.com

Good story about indirect costs from Bruce Lee at Forbes. www.forbes.com/sites/brucel...

Trump Administration Cuts Put Medical Progress at Risk: www.nytimes.com/2025/02/07/u...

Another assault on US competitiveness at a time when biomedicine is roaring with innovation, an own-goal in a high-stakes international tournament. Of course the real losers are American people needing medicines and cures. www.washingtonpost.com/health/2025/...

NIH plans to slash support for indirect research costs. Universities are already losing money with researchers. The consequence will be a reduction in the number of faculty positions opened to the new generation of scientists www.statnews.com/2025/02/07/n... via @statnews.com

With few role models, science and technology could seem a foreign world for many students. Now HHMI cancels a program to retain diverse students in undergraduate science and engineering programs. Hard times for equal opportunity www.statnews.com/2025/02/06/h... via @statnews.com

I am honored and humbled to have been nominated for the AAI Vanguard lecture this year. Particularly at a time of uncertainty for those of us who believe that the principle of equal opportunity must be a cornerstone of the foundation of America and Science in general www.aai.org/Awards/Caree...

White House Budget Office Orders Pause in All Federal GRANTS. This includes funds allocated by Congress: www.nytimes.com/2025/01/27/u...

The Ovarian Cancer Research Syndicate schedule is out from the @pennmedicine.bsky.social Ovarian Cancer Research Center. Great line up!

It seems that all NIH study section meetings have been temporarily cancelled until new notice. Unbelievable. www.science.org/content/arti...

Analysis of vector integration sites in 176 patients revealed no pathological insertions of transduced chimeric antigen receptors linked to secondary malignancies: rdcu.be/d68UH

Late-breaking/clinical trial abstract submissions for the "AACR IO – Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment Through Immunotherapy" conference in LAX runs from January 16 to January 23: www.aacr.org/meeting/aacr... www.aacr.org/about-the-aa...

Late-breaking abstracts are open for submission! Join the 2700+ record-breaking abstracts already submitted that are sure to make IMMUNOLOGY2025™ a success. Submit your amazing research for poster presentation before January 21. ow.ly/2vML50UC8Sz #immunology

Registrattion is open for the 11th International γδ T Cell Conference in Toronto (May 20-23, 2025) na.eventscloud.com/website/7048...

Now online in Cancer Discovery: Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma - by Tanjina Kader, Jia-Ren Lin, Clemens Hug, Ronny Drapkin, Sandro Santagata, et al. doi.org/10.1158/2159...

Are they really so clueless?: Kennedy’s Lawyer Has Asked the F.D.A. to Revoke Approval of the Polio Vaccine www.nytimes.com/2024/12/13/h...

Julio Chavez, MD, MS, summarizes some of the best research being presented at he 2024 American Society of Hematology Annual Meeting: www.targetedonc.com/view/epcorit...

Read the Letter From Nobel Laureates Urging That Mr. Kennedy Not be Confirmed www.nytimes.com/interactive/...

Out today: Oncolytic Virotherapy Plus Nivolumab Is Safe in Muscle-Invasive #BladderCancer, a #ResearchWatch summary of recent clinical findings by Roger Li, James J. Mulé, Jose R. Conejo-Garcia, and colleagues. aacrjournals.org/cdnews/news/...

This is a piece from Moffitt on the first patient with ovarian cancer receiving a second njection of CAR T cells. By understanding how the first injection targeting FSHR was effective, we could transform the management of this disease: moffitt.org/endeavor/arc... #OvarianCancer $ANIX

Neoantigen-specific CD8+ T-cell responses are NOT the primary determinants of response in dMMR tumors. Instead, clinical benefit is associated with cytotoxic molecules, NKG2D, nonclassical HLAs and butyrophilins, strongly pointing to a role for gamma/delta T cells aacrjournals.org/clincancerre...

In this new perspective in Science, my role model and favorite immunologist Randy Noelle discusses the development of CD40L antagonists to treat autoimmunity: www.science.org/doi/10.1126/...

The Ovarian Cancer Midwest Focus (OCMF) conference at Sanford Research in Sioux Falls, South Dakota was a total blast. The keynote speakers (Don Cleveland and Denise Montell) were amazing. The flash talks by the trainees were fascinating....and Casino Night was super fun. @pennmedicine.bsky.social

Patient responding to anti-FSHR CAR Is First To Receive Second CAR T Therapy for Ovarian Cancer

Inaugural AACR IO Conference on Discovery and Innovation in Cancer Immunology, chaired by Antoni Ribas. February 23-26, 2025, in Los Angeles. Learn more: bit.ly/3yOlXwm #AACRIO25

This article in press in Nature Medicine, led by Roger Li, shows how an oncolytic virus elicits complete remissions of cisplatin-inelegible bladder cancer through the assembly of IgA/IgG-producing Tertiary Lymphoid Structures: doi.org/10.1038/s415...

Duke Integrative Immunobiology department and Pharmacology & Cancer Biology joint search for tenure track assistant professor with focus on tumor immunology.